Clinical Trial Update: Genetic Variation in OCT1 and Response to Metformin [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial examining the influence of OCT1 genetic variation on metformin response in Type 2 Diabetes was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• metformin (metformin)

Snippet

Sponsor: Mayo Clinic | Conditions: Type 2 Diabetes | Phase 4 | Status: WITHDRAWN